Amneal Pharmaceuticals Files 8-K on Financials
Ticker: AMRX · Form: 8-K · Filed: May 3, 2024 · CIK: 1723128
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: AMRX
TL;DR
AMRX filed an 8-K on May 3rd detailing financial results and exhibits.
AI Summary
Amneal Pharmaceuticals, Inc. filed an 8-K on May 3, 2024, reporting on its results of operations and financial condition. The filing also includes information related to Regulation FD disclosure and financial statements and exhibits. The company's principal executive offices are located at 400 Crossing Blvd, Bridgewater, NJ 08807.
Why It Matters
This filing provides investors with crucial updates on Amneal Pharmaceuticals' financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine filing reporting financial information and does not indicate any immediate significant risks.
Key Players & Entities
- Amneal Pharmaceuticals, Inc. (company) — Registrant
- May 3, 2024 (date) — Filing date
- 400 Crossing Blvd, Bridgewater, NJ 08807 (location) — Principal executive offices
- 001-38485 (other) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing by Amneal Pharmaceuticals?
The primary purpose of this 8-K filing is to report on Amneal Pharmaceuticals' results of operations and financial condition, as well as to provide Regulation FD disclosures and financial statements and exhibits.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on May 3, 2024.
Where are Amneal Pharmaceuticals' principal executive offices located?
Amneal Pharmaceuticals' principal executive offices are located at 400 Crossing Blvd, Bridgewater, NJ 08807.
What is Amneal Pharmaceuticals' SEC File Number?
Amneal Pharmaceuticals' SEC File Number is 001-38485.
What is the SIC code for Amneal Pharmaceuticals?
The Standard Industrial Classification (SIC) code for Amneal Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 745 words · 3 min read · ~2 pages · Grade level 10.1 · Accepted 2024-05-03 06:14:36
Key Financial Figures
- $0.01 — stered Class A Common Stock, par value $0.01 per share AMRX The Nasdaq Stock Market
Filing Documents
- amrx-20240503.htm (8-K) — 29KB
- amrx-q12024ex991.htm (EX-99.1) — 315KB
- amneala.jpg (GRAPHIC) — 3KB
- 0001723128-24-000018.txt ( ) — 496KB
- amrx-20240503.xsd (EX-101.SCH) — 2KB
- amrx-20240503_lab.xml (EX-101.LAB) — 21KB
- amrx-20240503_pre.xml (EX-101.PRE) — 12KB
- amrx-20240503_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On May 3, 2024, Amneal Pharmaceuticals, Inc. (the "Company") issued a press release announcing its results for the first quarter ended March 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. In accordance with General Instruction B.2 of Form 8-K, the information under Item 2.02 of this report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
01 Regulation FD
Item 7.01 Regulation FD. Amneal will host a conference call and live webcast at 8:30 am Eastern Time on May 3, 2024, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. To access the call through a conference line, dial (833) 470-1428 (in the U.S.) with access code 172198. A replay of the conference call will be posted shortly after the call and will be available for seven days. For a list of toll-free international numbers, visit this website: https://www.netroadshow.com/events/global-numbers?confId=52762. The Company intends to publish an investor presentation that can be accessed at the Investors section of the Company's website, https://investors.amneal.com, under the "Events & Presentations" heading. In accordance with General Instruction B.2 of Form 8-K, the information referenced under Item 7.01 of this report is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are furnished herewith: Exhibit No. Description 99.1 Press release issued May 3, 2024. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 3, 2024 AMNEAL PHARMACEUTICALS, INC. By: /s/ Anastasios Konidaris Name: Anastasios Konidaris Title: Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)